Back

Unfractionated heparin or low molecular weight heparin in patients with acute pulmonary embolism: a meta-analysis of randomized controlled trials

2 September 2024 (13:00 - 13:50)
Organised by: Logo
Congress Presentation Part of: Novel anticoagulants and indications Anticoagulants ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Muhammad Haisum Maqsood

Houston Methodist DeBakey Heart & Vascular Center, Houston (United States of America)

7 More presentations in this session

Presentation thumbnail
Factor XI activity in ST-segment elevation myocardial infarction
Doctor M. Spagnolo (Catania, IT)
Abstract Slides Video
Presentation thumbnail
Direct oral anticoagulants or warfarin in patients with left ventricular thrombus: a meta-analysis of randomized clinical trials
Doctor M. Maqsood (Houston, US)
Abstract Slides Video
Presentation thumbnail
Direct Oral Anticoagulants versus Vitamin K Antagonists for the management of left ventricular thrombus after myocardial infarction: A meta-analysis
Doctor C. Gogos (Thessaloniki, GR)
Abstract Slides Video
Presentation thumbnail
Edoxaban for stroke prevention in routine practice patients with atrial fibrillation with and without atherosclerotic disease: a post-hoc sub-study of ETNA-AF-Europe
Doctor T. de Vries (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Antithrombotic strategies after cryptogenic stroke: a systematic review, pairwise, and network meta-analysis of randomized controlled trials
Doctor M. Abouzid (Poznan, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Novel anticoagulants and indications

The Event

Event poster

ESC Congress 2024

2 September 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
A meta-analysis of catheter-directed thrombolysis versus standard anticoagulation among patients with intermediate high risk pulmonary embolism
thumbnail
Congress Presentation
Antithrombotic strategies in acute PE
thumbnail
Congress Session
Risk assessment, biomarkers, treatments of acute pulmonary embolism: are we able to impact outcomes?

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources